Dr. Lipson received his Bachelor of Arts in economics from the University of Maryland in 1996. After working as a producer at CNN's "Larry King Live" for a few years, he completed a post-baccalaureate program at Georgetown University in Washington, DC. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at the Johns Hopkins Hospital, and completed his Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center.
Dr. Lipson's primary research interest is in early phase clinical trials for melanoma and other cutaneous malignancies. As a member of the Johns Hopkins Melanoma Program and the Immunology Program at the Kimmel Cancer Center, he focuses on evaluating novel therapies for patients with high risk or advanced disease. Dr. Lipson is a co-investigator on multiple trials, involving partners from both industry and academia, which address two major areas of opportunity in melanoma therapeutics: immunotherapy and molecular pathway inhibition. With an eye toward developing synergistic combinatorial therapies, Dr. Lipson is leading clinical research to test a cellular melanoma vaccine – melanoma GVAX – designed to stimulate T-cell immunity in melanoma patients. Other immunomodulatory therapies under investigation, including monoclonal antibodies such as anti-PD-1 and anti-B7-H1, have shown early promise in clinical trials led by Johns Hopkins investigators and may eventually be combined with vaccine therapies. Dr. Lipson and his colleagues recently authored a book chapter reviewing the state-of-the-art on these therapies.
In related research, Dr. Lipson is collaborating with Hopkins' expert Dr. Jim Herman to evaluate the impact of gene silencing (epigenetics) on immunoregulatory and anti-angiogenesis pathways in melanoma. These studies aim to better identify early stage melanoma patients who are at risk for disease progression, and to select those patients with advanced disease who are most likely to respond to immune-based therapy.
In addition to his research activities, Dr. Lipson conducts a regular clinical practice as part of the multidisciplinary Melanoma Program at Johns Hopkins. To learn more or schedule an appointment, call 410-616-7660.
Dr. Lipson is also the founder of “Seize the Days,” a non-profit organization that chronicles the stories of cancer patients who, with power and determination, find interesting and meaningful ways to add life to their days. For more information, visit http://seizethedays.org.